false
English
Catalog
2022 World Conference on Lung Cancer (ePosters)
EP05.02-008. Phase II Trial of Neoadjuvant Icotini ...
EP05.02-008. Phase II Trial of Neoadjuvant Icotinib Plus Chemotherapy for Stage II-IIIB EGFR-mutant Non-small-Cell Lung Cancer
Back to course
Pdf Summary
A phase II clinical trial is being conducted to evaluate the efficacy and safety of neoadjuvant therapy using icotinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, combined with chemotherapy for stage II-IIIB EGFR-mutant non-small-cell lung cancer (NSCLC). The trial aims to determine the impact of this treatment on major pathological response (MPR) as the primary endpoint, as well as secondary endpoints such as pathological complete response, overall survival, disease-free survival, objective response rate, disease control rate, and R0 resection rate. The study design involves giving eligible patients 8 weeks of oral icotinib, followed by 2 cycles of concurrent chemotherapy, and then surgical resection. Tumor response will be evaluated periodically following established criteria. The trial began in October 2021 and is expected to finish enrollment by December 2023 with 27 participants. The anticipated results are expected to provide promising treatment options for patients with stage II-IIIB EGFR-mutant NSCLC. The authors have reported no conflicts of interest.
Asset Subtitle
Fang-Liang Lu
Meta Tag
Speaker
Fang-Liang Lu
Topic
Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy
Keywords
neoadjuvant therapy
icotinib
EGFR tyrosine kinase inhibitor
chemotherapy
stage II-IIIB EGFR-mutant NSCLC
major pathological response
pathological complete response
overall survival
disease-free survival
tumor response
×
Please select your language
1
English
5
普通话
11
Dutch